Diagnostic value of a plasma microRNA signature in gastric cancer: A microRNA expression analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhou, Xin ^a   Zhu, Wei ^a   Li, Hai ^a   Wen, Wei ^a   Cheng, Wenfang ^a   Wang, Fang ^a   Wu, Yinxia ^b   Qi, Lianwen ^c   Fan, Yong ^c   Chen, Yan ^a   Ding, Yin ^d   Xu, Jing ^a   Qian, Jiaqi ^a   Huang, Zebo ^a   Wang, Tongshan ^a   Zhu, Danxia ^e   Shu, Yongqian ^a,f   Liu, Ping ^a,f  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b CLINICAL MEDICAL COLLEGE OF YANGZHOU UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d NANJING UNIVERSITY   (China)

^e THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^f NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

BLOOD; CASE CONTROL STUDY; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; STOMACH TUMOR;

CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 84931275702     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11251     Document Type: Article

References (47)

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136, E359-386; doi:10.1002/ijc.29210 (2015).
2. Jackson, C., Cunningham, D. & Oliveira, J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol. 20 Suppl 4, 34-36; doi:10.1093/annonc/mdp122 (2009).
3. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. doi:10.1038/nature13480 (2014).
4. Paoletti, X. et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA. 303, 1729-1737; doi:10.1001/jama.2010.534 (2010).
5. Waddell, T. et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol. 14, 481-489; doi:10.1016/S1470-2045(13)70096-2 (2013).
6. Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355, 11-20; doi:10.1056/NEJMoa055531 (2006).
7. Ychou, M. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 29, 1715-1721; doi:10.1200/JCO.2010.33.0597 (2011).
8. Liu, R. et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 47, 784-791; doi:10.1016/j.ejca.2010.10.025 (2011).
9. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 105, 10513-10518; doi:10.1073/pnas.0804549105 (2008).
10. Zhu, C. et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. doi:10.1038/bjc.2014.119 (2014).
11. Song, M. Y. et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One. 7, e33608; doi:10.1371/journal.pone.0033608 (2012).
12. Song, J. et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 57, 897-904; doi:10.1007/s10620-011-1981-7 (2012).
13. Xiang, M. et al. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun. 454, 210-214; doi:10.1016/j.bbrc.2014.10.064 (2014).
14. Sellars, M. J. et al. Real-time RT-PCR quantification of Kuruma shrimp transcripts: A comparison of relative and absolute quantification procedures. J Biotechnol. 129, 391-399; doi:10.1016/j.jbiotec.2007.01.029 (2007).
15. Kroh, E. M., Parkin, R. K., Mitchell, P. S. & Tewari, M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 50, 298-301; doi:10.1016/j.ymeth.2010.01.032 (2010).
16. Zhou, X. et al. Prognostic value of miR-21 in various cancers: An updating meta-analysis. PLoS One. 9, e102413; doi:10.1371/journal.pone.0102413 (2014).
17. Jensen, S. G. et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics. 12, 435; doi:10.1186/1471-2164-12-435 (2011).
18. Zhao, D. S. et al. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure. Cardiovasc Pathol. 22, 444-450; doi:10.1016/j.carpath.2013.04.001 (2013).
19. Zhu, C. et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 110, 2291-2299; doi:10.1038/bjc.2014.119 (2014).
20. Shiotani, A. et al. Identification of serum miRNAs as novel non-invasive biomarkers for detection of high risk for early gastric cancer. Br J Cancer. 109, 2323-2330; doi:10.1038/bjc.2013.596 (2013).
21. Kirschner, M. B. et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One. 6, e24145; doi:10.1371/journal.pone.0024145 (2011).
22. Li, B. S. et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 7, e41629; doi:10.1371/journal.pone.0041629 (2012).
23. Wang, B. & Zhang, Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 138, 1659-1666; doi:10.1007/s00432-012-1244-9 (2012).
24. Yao, Y. et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2, 963-970; doi:10.3892/mmr00000199 (2009).
25. Tan, Z. et al. miR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer. Mol Cell Biochem. 386, 223-231; doi:10.1007/s11010-013-1860-y (2014).
26. Wang, M. et al. Circulating miR-17-5p and miR-20a: Molecular markers for gastric cancer. Mol Med Rep. 5, 1514-1520; doi:10.3892/mmr.2012.828 (2012).
27. Cai, H. et al. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol. 30, 452; doi:10.1007/s12032-012-0452-0 (2013).
28. Kim, B. H., Hong, S. W., Kim, A., Choi, S. H. & Yoon, S. O. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 107, 505-510; doi:10.1002/jso.23271 (2013).
29. Li, X. et al. Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci. 14, 16226-16239; doi:10.3390/ijms140816226 (2013).
30. Wu, Q. et al. MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. J Cell Sci. 126, 4220-4229; doi:10.1242/jcs.127944 (2013).
31. Kulshreshtha, R. et al. A microRNA signature of hypoxia. Mol Cell Biol. 27, 1859-1867; doi:10.1128/MCB.01395-06 (2007).
32. Chan, Y. C., Banerjee, J., Choi, S. Y. & Sen, C. K. miR-210: The master hypoxamir. Microcirculation. 19, 215-223; doi:10.1111/j.1549-8719.2011.00154.x (2012).
33. Rotkrua, P. et al. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer. 108, 932-940; doi:10.1038/bjc.2013.30 (2013).
34. Hamilton, M. P. et al. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat Commun. 4, 2730; doi:10.1038/ncomms3730 (2013).
35. Wang, J. et al. Elevated Expression of miR-210 Predicts Poor Survival of Cancer Patients: A Systematic Review and Meta-Analysis. PLoS One. 9, e89223; doi:10.1371/journal.pone.0089223 (2014).
36. Omura, T. et al. Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. Oncol Rep. 31, 613-618; doi:10.3892/or.2013.2900 (2014).
37. Zeng, X. et al. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One. 7, e46367; doi:10.1371/journal.pone.0046367 (2012).
38. Zhi, F. et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol. doi:10.1093/neuonc/nou169 (2014).
39. Wang, J. et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2, 807-813; doi:10.1158/1940-6207.CAPR-09-0094 (2009).
40. Zhao, A., Li, G., Peoc'h, M., Genin, C. & Gigante, M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 94, 115-120; doi:10.1016/j.yexmp.2012.10.005 (2013).
41. Szabo, D. R. et al. Analysis of circulating microRNAs in adrenocortical tumors. Lab Invest. 94, 331-339; doi:10.1038/labinvest.2013.148 (2014).
42. Komatsu, S. et al. Plasma microRNA profiles: Identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma. Br J Cancer. doi:10.1038/bjc.2014.451 (2014).
43. Chen, X. et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997-1006; doi:10.1038/cr.2008.282 (2008).
44. Kosaka, N. et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 285, 17442-17452; doi:10.1074/jbc.M110.107821 (2010).
45. Arroyo, J. D. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 108, 5003-5008; doi:10.1073/pnas.1019055108 (2011).
46. Qiu, T. et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett. doi:10.1016/j.febslet.2014.02.054 (2014).
47. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25, 402-408; doi:10.1006/meth.2001.1262 (2001).